UroGen Pharma
UroGen Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological cancers. The company aims to enhance treatment options for patients by utilizing advanced technologies that address challenges in treatment delivery and effectiveness. UroGen Pharma emphasizes dynamic innovation to improve patient outcomes and has been active in presenting its advancements at major healthcare conferences. The company's product portfolio includes ZUSDURI™, a recently launched therapy, and UGN-103, which has shown a 77.8% complete response rate in a Phase 3 trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen Pharma's products leverage its platform technology to facilitate targeted delivery in the urinary tract, aiming to improve cancer treatment efficacy.
מי UroGen Pharma מגייסת כרגע.
רוצים גישה למאגר המלא?
היכנסו הביתה.
חברי בית מקבלים גישה למאגר חברות, משרות, מחקר קהילתי והערות פרטיות — הכל במקום אחד.